Novel agent promising for the treatment of schizophrenia
(HealthDay)—For patients with an acute exacerbation of schizophrenia, SEP-363856, a non-D2-receptor-binding drug that has agonist activity at trace amine-associated receptor 1 (TAAR1) and 5-hydroxytryptamine type 1A receptors, ...
Apr 16, 2020
0
7